Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 60
- Registration Number
- NCT02858921
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT02705963
- Locations
- 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸Karmanos Cancer Institute Karmanos Cancer Institute, Detroit, Michigan, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 95
- Registration Number
- NCT02703571
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Center, Boston, Massachusetts, United States
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT02684058
- Locations
- 🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago ., Chicago, Illinois, United States
🇺🇸Texas Children s Hospital Baylor College of Medicine, Houston, Texas, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02672358
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT02642042
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States
🇺🇸National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States
🇺🇸Grand Valley Oncology, Grand Junction, Colorado, United States
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
- Conditions
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT02625337
- Locations
- 🇳🇱
Antoni van Leeuwenhoek ziekenhuis, Amsterdam, NH, Netherlands
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02580708
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Tennessee Oncology, PLLC - The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02538627
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Vanderbilt, Nashville, Tennessee, United States
🇺🇸Northside Hospital, Sandy Springs, Georgia, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Interventions
- Drug: AfatinibDrug: CapivasertibDrug: BinimetinibDrug: AdavosertibProcedure: Biospecimen CollectionOther: Cytology Specimen Collection ProcedureDrug: Afatinib DimaleateDrug: DabrafenibDrug: DefactinibDrug: FexagratinibDrug: DasatinibDrug: IpatasertibProcedure: BiopsyDrug: CrizotinibDrug: Dabrafenib MesylateDrug: TaselisibDrug: SapanisertibDrug: PI3K-beta Inhibitor GSK2636771Drug: Defactinib HydrochlorideDrug: PalbociclibBiological: NivolumabDrug: CopanlisibDrug: UlixertinibBiological: Trastuzumab EmtansineDrug: Copanlisib HydrochlorideBiological: RelatlimabProcedure: Computed TomographyDrug: TrametinibBiological: PertuzumabDrug: ErdafitinibProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanDrug: LarotrectinibProcedure: EchocardiographyDrug: OsimertinibBiological: TrastuzumabDrug: Larotrectinib SulfateOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: VismodegibDrug: Sunitinib MalateProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.